Key result
Inhibition of platelet glycoprotein VI (GPVI) with drugs like glenzocimab and Revacept reduces thrombosis without impairing hemostasis, representing a promising antithrombotic approach.
Why the study?
Inhibition of platelet glycoprotein VI reduces thrombosis without impairing hemostasis, making it a promising antithrombotic approach.
Targeting platelet glycoprotein VI (GPVI) with investigational drugs like glenzocimab and Revacept represents a promising antithrombotic strategy that may reduce thrombosis without significantly increasing bleeding risk.
Answers are grounded in this paper and cite their sources.
May inform safer antithrombotic development in high-risk patients; leaves open phase 3 confirmation of net benefit.
Glycoprotein VI (GPVI), a key platelet receptor, mediates collagen-induced platelet activation and interacts with fibrin to promote thrombus growth. Studies demonstrate the mechanisms of GPVI in thrombosis, showing its inhibition reduces thrombosis without impairing hemostasis, consistent with the mild bleeding phenotype in GPVI-deficient individuals. GPVI is also implicated in inflammation and cancer. This review introduces the mechanism of GPVI in thrombosis and highlights two investigational GPVI-targeting drugs (glenzocimab and Revacept), summarizing current evidence and future directions for this promising antithrombotic approach.
No takes yet. Share an insight, caveat, or question.
Li et al. (2025) conducted a review in Thrombosis. GPVI-targeting drugs (glenzocimab and Revacept) was evaluated. Inhibition of platelet glycoprotein VI (GPVI) with drugs like glenzocimab and Revacept reduces thrombosis without impairing hemostasis, representing a promising antithrombotic approach.
Synapse has enriched 10 related papers. Consider them for comparative context: